CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Rhea-AI Summary

CVRx (NASDAQ: CVRX) presented new real-world evidence at THT 2025 demonstrating significant reductions in healthcare utilization with Barostim for heart failure patients. The study, published in the Journal of Cardiac Failure, analyzed data from 306 Barostim patients using the Premier Healthcare Database.

The analysis compared 12 months pre-implant data with almost two years post-implant (1.92±1.87 years), revealing remarkable reductions in hospital visits:

• 86% reduction in all-cause hospital visits
• 84% reduction in cardiovascular hospital visits
• 85% reduction in heart-failure hospital visits

All results were statistically significant (p<0.0001). The study also found significant reductions in length of hospital stays, providing important evidence for clinicians and payers considering the device for their patients.

Positive

• 86% reduction in all-cause hospital visits
• 84% reduction in cardiovascular hospital visits
• 85% reduction in heart-failure hospital visits
• Statistically significant results (p<0.0001) across all metrics
• Large sample size of 306 patients in real-world setting

Negative

• None.

Insights

Medical Device Market Analyst

The newly published real-world evidence for Barostim represents a significant milestone for CVRx, with profound implications for market adoption and revenue potential. The demonstrated 84-86% reduction in hospital visits across all categories is exceptional for medical devices in the heart failure space, where even 20-30% reductions are considered clinically meaningful.

The study's design and execution strengthen its credibility in several key aspects:

• The use of Premier Healthcare Database, covering over 1,300 institutions, provides comprehensive real-world data that payers and hospital systems find particularly compelling
• The nearly two-year follow-up period (1.92 years) demonstrates sustained benefits, important for chronic disease management
• The sample size of 306 patients offers statistical robustness that supports broader generalizability

From a commercial perspective, these results are likely to accelerate market adoption through multiple channels:

• The significant reduction in healthcare utilization presents a compelling cost-saving argument for payers, potentially leading to expanded coverage and streamlined authorization processes
• Hospitals and healthcare systems, increasingly focused on reducing readmission rates and length of stay, will find these outcomes particularly attractive
• The simultaneous publication in the Journal of Cardiac Failure and presentation at THT 2025 maximizes visibility within the medical community

The timing of this data release is strategically important as it coincides with growing pressure on healthcare systems to reduce costs while improving outcomes. The demonstrated reductions in hospital visits and length of stay directly address these priorities, potentially positioning Barostim as a cost-effective solution in the heart failure treatment paradigm.

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction

MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study demonstrated large and statistically significant reductions in hospital visits (hospitalizations and emergency department visits) and length of stay after Barostim implantation, compared to before. The research was published simultaneously and is available now in the Journal of Cardiac Failure.

“Despite contemporary medications, the clinical and economic burden of heart failure remains unacceptably high. This new study showing significant reductions in real-world healthcare utilization associated with the Barostim implant is critically important for clinicians and payers when considering this device for their patients,” said Jacob Abraham, MD, Section Head of Advanced Heart Failure at Providence Heart Institute in Portland, Ore. “While we know Barostim plus medications demonstrates long-term improvements in symptoms and quality of life, we now have compelling real-world evidence supporting a significant reduction in healthcare utilization as well.”

This analysis was performed using data from the Premier Healthcare Database, a large all-payer database including data from more than 1,300 institutions. Three hundred and six (306) Barostim patients were identified in the data set. Comparisons were performed for the 12 months prior to Barostim implant and for an average of almost two years post-implant (1.92±1.87 years). Length of stay was found to be significantly reduced. Hospital visits (hospitalizations and emergency department visits) were categorized as all-cause, cardiovascular, and heart failure related. The analysis found:

• 86% reduction in all-cause hospital visits (p<0.0001)
• 84% reduction in cardiovascular hospital visits (p<0.0001)
• 85% reduction in heart-failure hospital visits (p<0.0001)
  

“Congratulations to Dr. Jacob Abraham and co-authors for this important real-world analysis demonstrating remarkable reductions in healthcare utilization with Barostim,” said Dr. Philip Adamson, Chief Medical Officer of CVRx. “We believe this study adds to the growing and consistent body of evidence supporting the clinical utility of Barostim. This is another example of our commitment to further develop and disseminate a strong pipeline of clinical and economic data supporting the many benefits of this therapy.”

About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Media Contact:
Emily Meyers
651.338.6204
emeyers@cvrx.com        

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443.213.0501
ir@cvrx.com

FAQ

What were the key findings of CVRX's Barostim real-world study in 2025?

The study showed significant reductions in hospital visits: 86% reduction in all-cause visits, 84% in cardiovascular visits, and 85% in heart-failure visits, with all results being statistically significant (p<0.0001).

How many patients were included in CVRX's Barostim real-world study?

The study analyzed data from 306 Barostim patients using the Premier Healthcare Database, which includes data from more than 1,300 institutions.

What was the follow-up period in CVRX's Barostim healthcare utilization study?

The study compared 12 months of pre-implant data with an average of almost two years (1.92±1.87 years) post-implant data.

Where was CVRX's Barostim real-world evidence presented in 2025?

The real-world evidence was presented at the Technology and Heart Failure Therapeutics (THT) conference in Boston and simultaneously published in the Journal of Cardiac Failure.